Rapid COVID-19 tests ‘could miss one in four infected people’

Professor Deborah Williamson, co-lead author on the study and deputy director of the microbiological diagnostic unit public health laboratory at the Doherty Institute, said “considering the limitations in test sensitivity and the potential for rapid transmission in susceptible populations, particularly in hospital settings, careful consideration is required for implementation of antigen testing in a low prevalence setting.”

The state government had been hoping rapid and cheap antigen tests would become a key part of its testing strategy, with plans to roll them out at high-risk sites like meatworks, hospitals and aged care centres.

Under the plan, workers and visitors could be tested before they started work, stopping the virus at the gates.

The Victorian Department of Health has been contacted for comment.

Rapid antigen tests, which look for proteins being made by SARS-CoV-2, use nose or throat swabs to deliver a result in 15 to 30 minutes – much faster than standard PCR tests, which look for the virus’ genetic material.

Loading

However, they are several times less sensitive, requiring much higher levels of virus to build up before they can detect it.

In October, Victoria’s COVID-19 response commander Jeroen Weimar told The Age antigen testing “is just transformational”.

“If I can get tens of thousands of these antigen tests running by the end of the year, that allows you to step-change your testing. Do you apply it in workplaces? Do you apply it in schools? There are any number of places.”

Loading

After the federal government spent millions on COVID-19 antibody tests that were too inaccurate to use early in the pandemic, Victoria’s Health Department opted for a cautious approach, commissioning the Doherty Institute to validate the tests before they were rolled out.

The Doherty’s testing, published Wednesday in The Lancet Regional Health – Western Pacific, suggests the rapid tests will miss one in every four positive COVID-19 cases.

The antigen test’s sensitivity varied depending on when the people were tested, with best performance coming in the first few days after symptoms developed.

“However, we found many challenges around implementation of these tests, ranging from how to conduct the tests in a safe environment, choosing the population to test – symptomatic or asymptomatic – given the occurrence of false positives and negatives, to the additional waste that’s created by using the device,” Professor Williamson said.

“Given the high specificity, antigen-based tests may be most useful in rapidly triaging public health and hospital resources while expediting confirmatory PCR testing.”